Loading organizations...
§ Public · Tel Aviv, Israel
Clinical-stage oncology company developing and commercializing Alpha DaRT, a proprietary alpha-radiation cancer therapy for solid tumors.
Based in Jerusalem, Israel, Alpha Tau Medical is a clinical-stage oncology company that develops targeted alpha-radiation therapies to treat various solid tumors. The publicly traded medical device firm utilizes its proprietary Alpha DaRT technology to insert radioactive sources directly into tumors, causing irreparable DNA damage to cancer cells while sparing surrounding healthy tissue. Operating with approximately 121 to 125 employees, the company reached a $1 billion pre-merger valuation in 2021 before listing on the Nasdaq to fund ongoing clinical trials for skin, brain, and pancreatic cancers. Alpha Tau Medical has secured backing from notable investors including Shavit Capital, OurCrowd, and Medison Ventures, and generated $90 million in gross proceeds following a 2022 SPAC merger with Healthcare Capital Corp. The medical technology enterprise was founded in 2014 by Uzi Sofer, Itzhak Kelson, and Yona Keisari.
Alpha Tau Medical has raised $60.0M across 2 funding rounds.
Alpha Tau Medical has raised $60.0M in total across 2 funding rounds.
# Alpha Tau Medical: Clarification on Company Classification
Alpha Tau Medical is not a technology company in the traditional sense—it is a clinical-stage oncology therapeutics company[1][2]. This distinction is important for understanding its business model and market positioning.
Alpha Tau Medical develops and commercializes Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), an innovative approach to treating solid tumors using alpha particle radiation[1]. The company serves cancer patients with localized, unresectable, or recurrent tumors that lack curative standard-of-care options, including squamous cell carcinoma (SCC) of the skin and head/neck, as well as recurrent glioblastoma multiforme (GBM)[1].
The core problem Alpha Tau addresses is the limitation of conventional radiation therapy and surgery for certain cancer types—particularly tumors located near sensitive organs, difficult to access, or in patients unable to tolerate surgery[1]. Alpha DaRT's proprietary technology harnesses the therapeutic properties of alpha particles while overcoming their traditionally limited range, positioning it as a potential treatment option for nearly all solid tumors[1].
Alpha Tau Medical was founded in 2016 by CEO Uzi Sofer to develop the Alpha DaRT technology, which was invented by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University[1]. The company is incorporated in Israel[3]. Early traction came through a first-in-human clinical study launched in 2017 for locally advanced and recurrent SCC cancers of the skin and head/neck, with results published in the prestigious *International Journal of Radiation Oncology | Biology | Physics*[1]. This early success led to FDA Breakthrough Device Designations for both SCC treatment and recurrent GBM, validating the therapeutic approach and accelerating clinical development[1].
Alpha Tau operates within the precision oncology and radiation therapy innovation sector, riding the broader trend toward targeted, localized cancer treatments that minimize systemic toxicity. The timing is favorable as healthcare systems increasingly seek alternatives to conventional radiation and surgery for difficult-to-treat tumors. The company's technology represents a shift toward harnessing particle physics for therapeutic benefit—a trend gaining momentum as understanding of alpha particle biology advances.
As a NASDAQ-listed clinical-stage company (ticker: DRTS), Alpha Tau influences the biotech ecosystem by demonstrating investor appetite for novel radiation therapy approaches and validating the commercial potential of academic innovations from research institutions[2].
Alpha Tau's trajectory depends on successful advancement through clinical trials and regulatory approval for its lead indications. The company's ability to expand Alpha DaRT into additional solid tumor types—as its mission suggests—will determine whether it becomes a transformative oncology platform or remains focused on niche indications. Market adoption will hinge on clinical efficacy data, reimbursement pathways, and competitive positioning against emerging immunotherapy and targeted therapy combinations. The convergence of FDA support, expanding clinical evidence, and unmet patient needs positions Alpha Tau as a meaningful player in next-generation cancer treatment, though execution risk remains inherent to clinical-stage therapeutics.
Alpha Tau Medical has raised $60.0M across 2 funding rounds. Most recently, it raised $26.0M Series B in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2020 | $26M Series B | — | Aleph VC, Battery Ventures, Catapult Capital, Citi Ventures, Hillsven Capital, Norwest Venture Partners, OurCrowd, Recursive Ventures, SignalFire, The HIT Forge, Tribeca Venture Partners, UpWest, Clark Landry, Curtis LEE, Evan Williams, Michael Birch, Oliver Thylmann, Medison Ventures, Shavit Capital | Announced |
| Sep 1, 2018 | $34M Series A | Gary Leibler | Aleph VC, Battery Ventures, Bdmi Bertelsmann Digital Media Investments, Blue Collective, Catapult Capital, Citi Ventures, Hillsven Capital, Norwest Venture Partners, OurCrowd, OWL Capital, Primetime Partners, Recursive Ventures, SignalFire, The HIT Forge, Tribeca Venture Partners, UpWest, Clark Landry, Curtis LEE, Evan Williams, Michael Birch, Oliver Thylmann, Alan Patricof, SIR Ronnie Cohen, Meir Jakobsohn | Announced |
Alpha Tau Medical has raised $60.0M in total across 2 funding rounds.
Alpha Tau Medical's investors include Aleph VC, Battery Ventures, Catapult Capital, Citi Ventures, Hillsven, Norwest Venture Partners, OurCrowd, Recursive Ventures, SignalFire, The Hit Forge, Tribeca Venture Partners, UpWest.